Chemotherapy of Chagas' disease: The how and the why

Journal of Molecular Medicine

Volumn 77, Issue 3, 1999, Pages 332-338

  Urbina, Julio A ^a,b  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Chagas' disease; Chemotherapy; Nitrofurans; Nitroimidazoles autoimmunity; Sterol biosynthesis inhibitors; Trypanosoma cruzi

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL;

CHAGAS DISEASE; HUMAN; POLYMERASE CHAIN REACTION; REVIEW; STEROIDOGENESIS; TRYPANOSOMA CRUZI;

EID: 0033003357     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050359     Document Type: Review

References (63)

1. Pinto Dias JC (1992) Epidemiology of Chagas disease. In: Wendel S, Brener Z, Camargo ME, Rassi A (eds) Chagas disease (American trypanosomiasis): its impact on transfusion and clinical medicine. ISBT Brazil, São Paulo, pp 49-80
2. Docampo R, Schmuñis GA (1997) Sterol biosynthesis inhibitors: potential chemotherapeutics against Chagas disease. Parasitol Today 13:129-130
3. World Bank (1994) World development report 1994: investing in health. Oxford University Press, Oxford
4. de Castro Solange L (1993) The challenge of Chagas disease chemotherapy: an update of drugs assayed against Trypansoma cruzi. Acta Trop 53:83-98
5. Rassi A, Luquetti AO (1992) Therapy of Chagas disease. In: Wendel S, Brener Z, Camargo ME, Rassi A (eds) Chagas disease (American trypanosomiasis): its impact on transfusion and clinical medicine. ISBT Brazil, São Paulo, pp 237-247
6. Croft SL, Urbina JA, Brun R (1997) Chemotherapy of human leishmaniasis and trypanosomiasis. In: Hide G, Mottram JC, Coombs GH, Holmes PH (eds) Trypanomiasis and leishmaniasis. CAB International, London, pp 245-257
7. Quintas LEM, Siqueira-Batista R (1996) Inmunologia. In: Siqueira-Batista R, Corrêa AD, Huggins DW (eds) Molestia de Chagas. Cultura Medica, Rio de Janeiro, pp 53-74
8. Brener Z, Gazzinelli RT (1997) Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 114:103-110
9. Lyr H (1995) Modern selective fungicides. Fisher, Jena
10. Yamaguchi H, Kobayashi GS, Takahashi H (1992) Recent progress in antifungal chemotherapy. Dekker, New York
11. Docampo R, Moreno SNJ, Turrens JF, Katzin AM, Gonzales-Cappa SM, Stoppani AOM (1981) Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol Biochem Parasitol 3:169-180
12. McCabe RE, Remington JS, Araujo FG (1984) Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection against a lethal infection with the organism. J Infect Dis 150:594-601
13. McCabe RE, Remington JS, Araujo FG (1986) In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg 35:280-284
14. McCabe RE, Remington JS, Araujo FJ (1987) Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi. Trans R Soc Trop Med Hyg 81:613-615
15. Raether W, Seidenath H (1984) Ketoconazole and other potent antimycotic azoles exhibit pronounced activity against Trypanosoma cruzi, Plasmodium berghei and Entamoeba histolytica in vivo. Z Parasitenkd 70:135-138
16. Beach DH, Goad LJ, Holz GG Jr (1986) Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi. Biochem Biophys Res Commun 135:851-856
17. Goad LJ, Berens RL, Marr JJ, Beach DH, Holz GG Jr (1989) The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Mol Biochem Parasitol 32:179-190
18. Larralde G, Vivas J, Urbina JA (1988) Concentration and time dependence of the effects of ketoconazole on growth and sterol biosynthesis in Trypanosoma (Schizotrypanum) cruzi epimastigotes. Acta Cient Venez 39:140-146
19. Urbina JA, Lazardi K, Aguirre T, Piras MM, Piras R (1988) Antiproliferative synergism of the allylamine SF-86327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 32:1237-1242
20. Urbina JA, Lazardi K, Aguirre T, Piras MM, Piras R (1991) Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 35:730-735
21. Lazardi K, Urbina JA, DeSouza W (1991) Ultrastructural alterations induced by ICI 195,739, a bis triazole with strong antiproliferative action against Trypanosma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 35:736-740
22. Urbina JA, Lazardi K, Marchan E, Visbal G, Aguirre T, Piras MM, Piras R, Maldonado RA, Payares G, DeSouza W (1993) Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vivo and in vitro studies. Antimicrob Agents Chemother 37:580-591
23. 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol Biochem Parasitol 73:199-210
24. 24(25)-sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy 42:294-307
25. McCabe RE (1988) Failure of ketoconazole to cure chronic murine Chagas disease. J Infect Dis 158:1408-1409
26. Moreira AAB, DeSouza HBWT, Amato Neto V, Matsubara L, Pinto PLS, Tolezano JE, Nunes EV, Okumura M (1992) Avaliacão da atividade terapêutica do itraconazol nas infecçoes crônicas, experimental e humana, pelo Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 34:177-180
27. Brener Z, Cançado JR, Galvão LM, da Luz ZMP, Filardi LdS, Pereira MES, Santos LMT, Cançado CB (1993) An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz 88:149-153
28. Boyle FT, Gilman DJ, Gravestock MB, Wardleworth JM (1988) Synthesis and structure-activity relationships of a novel antifungal agent ICI 195,739. In: St. Georgiev V (ed) Antifungal drugs. Annals of the New York Academy of Sciences, New York, Vol. 544 :86-100
29. Ryley JF, McGregor S, Wilson RG (1988) Activity of ICI 195,739 -a novel orally active bistriazole - in rodent models of fungal and protozoal infections. In: St. Georgiev V (ed) Antifungal drugs. Annals of the New York Academy of Sciences, New York, Vol. 544:310-328
30. Maldonado RA, Molina J, Payares G, Urbina JA (1993) Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas disease. Antimicrob Agents Chemother 37:1353-1359
31. Urbina JA, Payares G, Molina J, Sanoja C, Liendo A, Lazardi K, Piras MM, Piras R, Perez N, Wincker P, Ryley JF (1996) Cure of short- and long-term experimental Chagas disease using D0870. Science 273:969-971
32. Liendo A, Lazardi K, Urbina JA (1998) Antiproliferative effects of D0870 on Trypanosoma (Schizotrypanum) cruzi. J Antimicrob Chemother 41:197-205
33. Urbina JA (1997) Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 117:S91-S99
34. Wincker P, Britto C, Borges-Pereira J, Cardoso MA, Oelemann W, Morel CM (1994) Use of a simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood samples from chronic chagasic patients in a rural endemic area. Am J Trop Med Hyg 51:771-777
35. Britto C, Cardoso MA, Wincker P, Morel CM (1993) A simple protocol for the physical cleavage of Trypanosoma cruzi kinetoplast DNA present in blood samples and its use in polymerase chain reaction (PCR)-based diagnosis of chronic Chagas disease. Mem Inst Oswaldo Cruz 88:171-172
36. Britto C, Cardoso MA, Monteiro Vanni CM, Hasslocher-Moreno A, Xavier SS, Oelemann W, Santoro A, Pirmez C, Morel CM, Wincker P (1995) Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology 110:241-247
37. Molina J, Araújo MSS, Pereira MES, Urbina JA, Brener Z (1996) Therapeutic effects of the triazole D0870 inhibitor of sterol biosynthesis on different Trypanosoma cruzi strains. Mem Inst Oswaldo Cruz 91 [Suppl] 1:515
38. Clemons KV, Hanson LH, Stevens DA (1993) Activities of the triazole D0870 in vitro and against murine blastomycosis. Antimicrob Agents Chemother 37:1177-1179
39. De Wit S, O'Doherty E, Smith RP, Yates R, Clumeck N (1995) Pharmacokinetics of two multiple dosing regimens of D0870 in HIV positive patients: a phase I study. ICAAC Abstr 35:F97
40. Sugar AM, Liu X-P (1996) In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 40:1314-1316
41. Perfect JR, Cox GM, Dodge RK, Schell WA (1996) In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 40:1910-1913
42. Pfaller MA, Messer S, Jones RN (1997) Activity of a new triazole, SCH 56592, compared with those of four other antifungal agets tested against clinical isolates of Candida spp and Saccharomyces cerevisiae. Antimicrob Agents Chemother 41:233-235
43. Urbina JA, Payares G, Sanoja C, Contreras LM, Liendo A, Piras MM, Piras R (1996) In vitro and in vivo antiproliferative effects of SCH 56592 against Trypanosoma cruzi, the causative agent of Chagas disease. ICAAC Abstr 36:F102
44. Urbina JA, Contreras LM, Liendo A, Payares G, Sanoja C, Molina J, Piras MM, Piras R, Perez N, Wincker P, Loebenberg D Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 42:1771-1777
45. Girijavallabhan VM, Saksena AK, Lovey RG, Bennet F, Pike RE, Wang H, Pinto P, Liu YT, Patel N, Ganguly AK (1995) SCH 56592, a novel broad spectrum antifungal agent. ICAAC Abstr 35:F61
46. Nomeir A, Kumari P, Hilbert MJ, Loebenberg D, Cacciapuoti A, Menzel Jr J, Moss Jr E, Hare R, Miller GH, Cayen MN, Lin CC (1995) Comparative pharmacokinetics of a new triazole antifungal agent, SCH 56592, in mice, rats, rabbits, dogs and cynomolgus monkeys. ICAAC Abstr 35:F68
47. Laughlin M, Pai S, Menon S, Nomeir A, Colucci R, Affrime M, Kosoglou T (1997) SCH 56592: rising multiple-dose safety, tolerance, and pharmacokinetic evaluation in healthy volunteers. ICAAC Abstr 37:A87
48. Cunha-Neto E, Duranti M, Gruber A, Zingales B, De Messias I, Stolf N, Bellotti G, Patarroyo ME, Kalil J (1995) Autoinmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an inmunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci USA 92:3541-3545
49. Kalil J, Cunha-Neto E (1996) Autoimmunity in Chagas disease cardiomyopathy: fulfilling the criteria at last? Parasitol Today 12:396-399
50. Bestetti RB (1996) Role of parasites in the pathogenesis of Chagas' cardiomyopathy. Lancet 347:913-914
51. Bestetti RB (1997) Should benznidazole be used in chronic Chagas' disease? Lancet 349:653
52. Jones EM, Colley DG, Tosies S, Reis Lopes E, Vnencak-Jones CL, McCurley TL (1993) Amplification of a Trypanosoma cruzi DNA sequence from inflamatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg 48:348-357
53. Brandariz S, Schijman A, Vigliano C, Arteman P, Viotti R, Beldjord C, Levin MJ (1995) Detection of parasite DNA in Chagas' heart disease. Lancet 346:1370-1371
54. Brandariz S, Schijman A, Vigliano C, Viotti R, Levin MJ (1996) Role of parasites in the pathogenesis of Chagas' cardiomyopathy. Lancet 347:914
55. Levin MJ (1996) In chronic Chagas heart disease, don't forget the parasite. Parasitol Today 12:415-416
56. Tarleton RL, Zhang L, Downs MO (1997) "Autoinmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue. Proc Natl Acad Sci USA 94:3932-3937
57. Rosenbaum MB, Chiale PA, Schejtman D, Levin MJ, Elizari MV (1994) Antibodies to beta-adrenergic receptors disclosing agonist-like properties in idiopathic dilated cardiomyopathy and Chagas' heart disease. J Cardiovasc Electrophysiol 5:367-375
58. Kaplan D, Ferrari I, Lopez-Bergami P, Mahler E, Levitus G, Chiale P, Hoebeke J, Van Regenmortel MHV, Levin MJ (1997) Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus. Proc Natl Acad Sci USA 94:10301-10306
59. Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA (1991) Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz 86:187-200
60. Viotti R, Vigliano C, Armenti H, Segura E (1994) Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127:151-162
61. Andrade ALS, Zicker F, Oliveira RM, Silva SA, Luquetti A, Travassos LR, Almeida IC, Andrade SS, Andrade JG, Martelli CMT (1996) Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-1413
62. Andrade ALS, Zicker F (1997) Should benznidazole be used in chronic Chagas' disease? Lancet 349:653
63. Burleigh BA, Andrews NW (1995) The mechanism of Trypanosoma cruzi invasion of mammalian cells. Annu Rev Microbiol 49:175-200